SELECT Pooled Analysis: Safety of Upadacitinib in Patients With Rheumatoid Arthritis

APLAR 2019: Brisbane, Australia; April 8-11, 2019; JCR: Kyoto, Japan; April 15-17, 2019
EULAR: Madrid, Spain; June 12-15, 2019
Analysis of pooled data from 5 phase III RCTs in RA patients suggests similarities and differences in safety profile of upadacitinib vs methotrexate or adalimumab.
Format: Microsoft PowerPoint (.ppt)
File Size: 193 KB
Released: July 1, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Lilly
Sanofi Genzyme and Regeneron Pharmaceuticals

Related Content

Experts discussion of recent efficacy and safety data on JAK inhibitors in managing RA, from Clinical Care Options (CCO)

Stanley B. Cohen, MD person default Janet Pope, MD, MPH, FRCPC Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: January 10, 2023 Expired: January 9, 2024

Drs. Stanley Cohen and Janet Pope on the latest clinical trials and real-world evidence regarding JAK inhibitor efficacy from Clinical Care Options (CCO)

Vivian P. Bykerk, MD, FRCPC Stanley B. Cohen, MD person default Janet Pope, MD, MPH, FRCPC person default Vibeke Strand, MD, MACR, FACP Released: January 9, 2023

Clinical Care Options (CCO): infectious diseases physician on use of postexposure chemoprophylaxis for patients with rheumatologic disorders who are at high-risk for influenza complications

Tracy Zivin-Tutela, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 9, 2022 Expired: December 8, 2023

Clinical Care Options (CCO) presents expert faculty discussing options for the treatment and care of patients with rheumatic disease during flu season.

Cassandra Calabrese, DO Released: December 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings